Strategic Partnering for Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strategic Partnering for Manufacturing
Eisai and Biogen Idec pursue an innovative approach to capacity management.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 118-120

Mixed sourcing strategy

For both Biogen Idec and Eisai, the new manufacturing partnership is part of a sourcing strategy in which both internal capacity and CMO relationships are key components. Biogen Idec has traditionally outsourced its fill-and-finish requirements while maintaining its own large molecule API manufacturing facilities. While it will manufacture its own products at the leased Eisai facility, it has also outsourced the manufacture of a new solid-dose product in its pipeline. Eisai plans to continue to invest in its injectables capabilities to support its own pipeline, and sees the additional volume from Biogen Idec as helping to justify the additional investment. However, Eisai will use CMOs where appropriate: it recently announced a three-year master supply agreement with DSM Pharmaceutical Products for manufacture of eribulin mesylate (Halaven) at DSM’s Greenville, N.C., injectables manufacturing facility.

Whether the partnership between Biogen Idec and Eisai is just a one-off event or becomes a model for the industry remains to be seen. It may be that unique factors like geographic proximity, interpersonal dynamics, and complementary needs facilitated an innovative approach that may be hard to duplicate. Or it may be that having seen this example of a new partnership approach, other bio/pharmaceutical companies start looking for innovative alternatives to addressing their manufacturing requirements.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here